NICE negative on Avastin in breast cancer, even in taxane subgroup
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has again said it will not be recommending Roche's Avastin (bevacizumab) in combination with capecitabine for metastatic breast cancer. Roche has criticised NICE's failure to recognise a particular patient group that could benefit.